argenx SE Reg.Shares (Sp.ADRs)/1 EO -,10
- BID
760
- ASK
770
- 7 Units6 Units
- 07/21, 15:52:57 PM
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
51.23%
Market Cap
45.98 Bil.
P/E Ratio
39.77
Dividend Yield
0.00 %
Earnings per Share
18.74 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | ||
| LAST PRICE | 755 G | 0 Units |
| PRICE DETERMINATION TIME | 07/21/2026 / 03:32:21 PM | |
| DAILY VOLUME (UNITS) | 0 | |
| DAILY HIGH / LOW | 755 | 740 |
| PREV. DAY'S PRICE | 735 | (07/20) |
| CHANGE DAY BEFORE | +20.00 | 2.72 % |
| 52 WEEK HIGH / LOW | 830 (07/02) | 474 (07/22) |
Key Figures (in EUR)
| 2023 | 2024 | 2025 | 2026e | 2027e | |
|---|---|---|---|---|---|
EARNINGS PER SHARE | -4.78 | 12.84 | 18.74 | 22.82 | 29.69 |
DIVIDENDS PER SHARE | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
DIVIDEND YIELD IN % | 0.00 % | 0.00 % | 0.00 % | - | - |
DIVIDEND GROWTH IN % | - | - | - | - | - |
PRICE - EARNINGS RATIO | - | 44.27 | 39.77 | 32.96 | 25.34 |
PRICE - BOOK RATIO | 5.50 | 6.80 | 7.11 | - | - |
PRICE - SALES RATIO | 17.71 | 18.33 | 13.33 | - | - |
PRICE - CASH FLOW RATIO | - | 1,389.36 | 65.29 | - | - |
Master Data
| WKN | A2H9WD |
| ISIN | US04016X1019 |
| SYMBOL | 1AEA |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | ARGENS SE SP.ADR/1 -,10 |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | US Dollar |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | 62.56 Mil. |
| MARKET CAPITALISATION | 45.98 Bil. |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | -3.92 % | -4.55 % | 4.26 % | 6.52 % | 51.23 % | 57.05 % | 180.53 % | 5.00 % |
| HIGH | 765.00 | 830.00 | 830.00 | 830.00 | 830.00 | 830.00 | 830.00 | 830.00 |
| LOW | 730.00 | 730.00 | 645.00 | 565.00 | 474.00 | 306.00 | 224.00 | 565.00 |
Dividende
pro Aktie
ARGENS SE SP.ADR/1 -,10 does not deliver dividend information
Company profile
argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. It operates through the following geographical segments: United States, Japan, EMEA, and China. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Amsterdam, the Netherlands.
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.